Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Lumos Pharma (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focusing on rare disease therapeutics, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York City. The company's management will be available for one-on-one meetings on September 9th and 10th.
Key details include:
- An on-demand corporate presentation available from September 9th at 7:00 AM EDT
- A webcast accessible for 90 days after the event
- The presentation will also be available on Lumos Pharma's website
Investors can contact H.C. Wainwright sales representatives or Lumos Pharma's Investor Relations to schedule meetings with management during or after the conference.
Lumos Pharma (NASDAQ:LUMO), un'azienda biofarmaceutica in fase clinica che si concentra sulle terapie per malattie rare, ha annunciato la sua partecipazione alla 26ª Conferenza Annuale Globale sugli Investimenti H.C. Wainwright che si terrà dal 9 all'11 settembre 2024 a New York. La direzione dell'azienda sarà disponibile per incontri one-on-one il 9 e 10 settembre.
Dettagli chiave includono:
- Una presentazione aziendale on-demand disponibile dal 9 settembre alle 7:00 AM EDT
- Un webcast accessibile per 90 giorni dopo l'evento
- La presentazione sarà disponibile anche sul sito web di Lumos Pharma
Gli investitori possono contattare i rappresentanti commerciali di H.C. Wainwright o le Relazioni con gli Investitori di Lumos Pharma per pianificare incontri con la direzione durante o dopo la conferenza.
Lumos Pharma (NASDAQ:LUMO), una empresa biofarmacéutica en etapa clínica que se centra en terapias para enfermedades raras, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright que se llevará a cabo del 9 al 11 de septiembre de 2024 en Nueva York. La gestión de la empresa estará disponible para reuniones individuales el 9 y 10 de septiembre.
Detalles clave incluyen:
- Una presentación corporativa a demanda disponible a partir del 9 de septiembre a las 7:00 AM EDT
- Una transmisión web accesible durante 90 días después del evento
- La presentación también estará disponible en el sitio web de Lumos Pharma
Los inversores pueden contactar a los representantes de ventas de H.C. Wainwright o a las Relaciones con Inversores de Lumos Pharma para programar reuniones con la dirección durante o después de la conferencia.
Lumos Pharma (NASDAQ:LUMO), 희귀 질병 치료에 집중하는 임상 단계의 생명공학 회사가 2024년 9월 9일부터 11일까지 뉴욕에서 개최되는 H.C. 웨인라이트 제26회 연례 글로벌 투자 회의에 참가한다고 발표했습니다. 회사 경영진은 9일과 10일에 개별 미팅을 위해 대기할 것입니다.
주요 세부 사항은 다음과 같습니다:
- 9월 9일 오전 7:00 EDT부터 이용 가능한 주문형 기업 프레젠테이션
- 이벤트 이후 90일 동안 접근할 수 있는 웹캐스트
- 프레젠테이션은 Lumos Pharma의 웹사이트에서도 이용 가능합니다.
투자자는 H.C. 웨인라이트의 영업 직원이나 Lumos Pharma의 투자 관계부서에 연락하여 회의 일정을 잡을 수 있습니다.
Lumos Pharma (NASDAQ:LUMO), une entreprise biopharmaceutique en phase clinique axée sur les traitements pour les maladies rares, a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur l'Investissement H.C. Wainwright qui se tiendra du 9 au 11 septembre 2024 à New York. La direction de l'entreprise sera disponible pour des réunions individuelles les 9 et 10 septembre.
Détails clés :
- Une présentation d'entreprise à la demande disponible à partir du 9 septembre à 7h00 EDT
- Un webinaire accessible pendant 90 jours après l'événement
- La présentation sera également disponible sur le site web de Lumos Pharma
Les investisseurs peuvent contacter les représentants commerciaux de H.C. Wainwright ou les Relations avec les Investisseurs de Lumos Pharma pour planifier des réunions avec la direction pendant ou après la conférence.
Lumos Pharma (NASDAQ:LUMO), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf Therapien für seltene Krankheiten konzentriert, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright angekündigt, die vom 9. bis 11. September 2024 in New York City stattfindet. Das Management des Unternehmens steht am 9. und 10. September für Einzelgespräche zur Verfügung.
Wichtige Einzelheiten sind:
- Eine on-demand Unternehmenspräsentation, die ab dem 9. September um 7:00 Uhr EDT verfügbar ist
- Ein Webcast, der 90 Tage nach der Veranstaltung zugänglich ist
- Die Präsentation wird auch auf der Website von Lumos Pharma verfügbar sein
Investoren können die Vertriebsmitarbeiter von H.C. Wainwright oder die Investor Relations von Lumos Pharma kontaktieren, um Meetings mit dem Management während oder nach der Konferenz zu planen.
- None.
- None.
AUSTIN, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9th – 11th in New York City. Lumos Pharma management will be present to host one-on-one meetings on Monday and Tuesday, September 9th and 10th.
H.C. Wainwright 26th Annual Global Investment Conference: September 9th – 11th
| Title: | Lumos Pharma Corporate Presentation (On-Demand) | |
| Date/Time: | September 9th at 7:00AM EDT | |
| Webcast Link: | Register here | |
| 1x1 Meetings: | Monday-Tuesday, September 9th-10th | |
The presentation webcast can be downloaded at 7:00AM EDT on September 9th and will be available for 90 days thereafter. The webcast can also be accessed on the Company’s website under Events & Presentations in the Investors & Media section. Please contact your H.C. Wainwright salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with management at the conference or thereafter.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
FAQ
When is Lumos Pharma (LUMO) participating in the H.C. Wainwright Global Investment Conference?
What type of meetings will Lumos Pharma (LUMO) host at the conference?
When will Lumos Pharma's (LUMO) corporate presentation be available at the conference?
How long will Lumos Pharma's (LUMO) presentation webcast be accessible?
Where else can investors access Lumos Pharma's (LUMO) presentation from the conference?
